Related Experiment Videos
Papillomavirus-like particles and HPV vaccine development
1Laboratory of Cellular Oncology, National Cancer Institute, Bethesda, MD 20892, USA.
Seminars in Cancer Biology
|December 1, 1996
Summary
Human papillomavirus-like particles (VLPs) show promise as a vaccine to prevent HPV infection and cervical cancer. Animal studies demonstrate VLP efficacy, supporting the initiation of human trials for HPV VLP-based vaccines.
Area of Science:
- Virology
- Immunology
- Vaccinology
Background:
- Human papillomavirus (HPV) infection is a major cause of cervical cancer.
- HPV-like particles (VLPs) are self-assembled from the L1 capsid protein.
- VLPs are being explored as a potential subunit vaccine candidate.
Purpose of the Study:
- To evaluate the immunogenicity and protective potential of HPV VLPs in preclinical models.
- To assess the feasibility of developing VLP-based vaccines against HPV infection.
- To discuss considerations for human clinical trials of HPV VLP vaccines.
Main Methods:
- High-level expression of papillomavirus L1 protein in non-mammalian cells.
- Self-assembly of L1 proteins into virus-like particles (VLPs).
- Immunization of animals with purified VLPs and assessment of antibody responses and protection.
Main Results:
- Purified VLPs induced high titers of type-specific antibodies against conformational L1 epitopes.
- These antibodies neutralized homologous virions in vitro.
- VLPs demonstrated protection against experimental challenge in several animal models.
Conclusions:
- HPV VLPs are attractive candidates for a subunit vaccine against HPV infection and cervical cancer.
- Encouraging animal study results support the initiation of human trials.
- Further considerations are necessary for designing effective human clinical trials.